Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 7/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA4 | P22748 | 4/20 | 0.45 |
| ▸ | CA5A | P35218 | 4/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.41 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619733 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL313683 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL13928976 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL9616862 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL6230386 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL3972810 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL4619592 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL8089407 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL314060 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA | |
| SCHEMBL314061 | 1.00 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10CA2OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209477-A1 | COMPOSITIONS FOR BIOMEDICAL APPLICATIONS | UNIV MASSACHUSETTS MEDICAL (US) | 2015-07-30 | — | — | US | disclosed |
| US-9023813-B2 | Synthesis and use of glycoside derivatives of propofol | NuTek Pharma Ltd. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150119346-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | Chromatin Technologies | 2015-04-30 | — | — | US | disclosed |
| US-8921533-B2 | Glycosylated valproic acid analogs and uses thereof | Chromatin Technologies (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130029924-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | Chromatin Technologies (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-11-22 | — | — | US | disclosed |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | NuTek Pharma Ltd. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142141-A1 | SYNTHESIS AND USE OF GLYCOSIDE PRO-DRUG ANALOGS | NuTek Pharma Ltd. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142147-A2 | SYNTHESIS AND USE OF GLYCOSIDE DERIVATIVES OF PROPOFOL | NuTek Pharma Ltd. (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2434891-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2007050892-A2 | CAMPTOTHECIN DERIVATIVES AND IMPROVED SYNTHETIC METHODS | GLYCONIX CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070037756-A1 | Compositions and methods for the prevention and treatment of circulatory conditions | LEADTREK, INC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20030004321-A1 | Glycosylated analogs of fusidic acid | TUINMAN ROELAND (US) | 2003-01-02 | — | — | US | disclosed |
| US-6462182-B1 | CHEMOTHERAPY, MICROBIAL INFECTIONS; ENHANCED SOLUBILITY; CATALYSIS, HYDROLYSIS | THE UNIVERSITY OF MICHIGAN | 2002-10-08 | — | — | US | disclosed |
| US-6103884-A | REACTING UNMODIFIED FUSIDIC ACID, A DERIVATIZING AGENT, AND A CATALYST TO PRODUCE A GLYCOSYLATED ANALOG, THEN HYDROLYZING WITHOUT AFFECTING THE ACETATE GROUP AT THE C-16 POSITION; FOR DIFFERENT SOLUBILITY PROPERTIES | THE UNIVERSITY OF MICHIGAN (US) | 2000-08-15 | — | — | US | disclosed |
| US-5932709-A | REACTING DISACCHARIDE WITH PROTECTING REAGENT, REACTING PRODUCT WITH HALOGENATING AGENT, REACTING WITH REDUCING AGENT TO FORM DISACCHARIDE GLYCAL | UNIVERSITY OF MICHIGAN (US) | 1999-08-03 | — | — | US | disclosed |
| US-5677286-A | ANTICANCER AGENTS | THE UNIVERSITY OF MICHIGAN (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1996034003-A1 | GLYCOSYLATED ANALOGS OF CAMPTOTHECIN | UNIVERSITY OF MICHIGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5409902-A | Oral hygiene compositions containing glyceroglycolipids as antiplaque compounds | LEVER BROTHERS COMPANY (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0551674-A1 | Oral hygiene compositions containing glyceroglycolipids as antiplaque compounds | UNILEVER N.V. (NL) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | GCG, CYP3A5, UGT1A6 | CYP2D6 11/4885THRB 2875/4885HSD17B10 1558/4885 |
| US-20130029924-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | HDAC3, VGF, HDAC1 | CYP2D6 144/4885THRB 3349/4885HSD17B10 363/4885 |
| US-20150119346-A1 | GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF | HDAC3, VGF, HDAC1 | CYP2D6 144/4885THRB 3349/4885HSD17B10 363/4885 |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | CYP3A5, CYP3A4, UGT1A4 | CYP2D6 10/4885THRB 2227/4885HSD17B10 1340/4885 |
| US-20070037756-A1 | Compositions and methods for the prevention and treatment of circulatory conditions | SELP, PTGER3, PLTP | CYP2D6 2018/4885THRB 3689/4885HSD17B10 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.